Latest Insider Transactions at Cerevel Therapeutics Holdings, Inc. (CERE)
This section provides a real-time view of insider transactions for Cerevel Therapeutics Holdings, Inc. (CERE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cerevel Therapeutics Holdings, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cerevel Therapeutics Holdings, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 08
2022
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-78.72%
|
$370,000
$37.75 P/Share
|
|
Aug 08
2022
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+44.05%
|
$30,000
$3.5 P/Share
|
|
Aug 05
2022
|
Abraham Ceesay President |
SELL
Open market or private sale
|
Direct |
38,424
-100.0%
|
$1,229,568
$32.5 P/Share
|
|
Aug 05
2022
|
Abraham Ceesay President |
BUY
Exercise of conversion of derivative security
|
Direct |
38,424
+50.0%
|
$499,512
$13.17 P/Share
|
|
Aug 05
2022
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-88.09%
|
$640,000
$32.5 P/Share
|
|
Aug 05
2022
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+46.83%
|
$60,000
$3.5 P/Share
|
|
Jul 20
2022
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-90.24%
|
$750,000
$30.0 P/Share
|
|
Jul 20
2022
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+47.43%
|
$75,000
$3.5 P/Share
|
|
Jul 06
2022
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,105
-29.01%
|
$35,360
$32.5 P/Share
|
|
Jul 06
2022
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,105
+22.49%
|
$3,315
$3.5 P/Share
|
|
Jul 05
2022
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-90.24%
|
$750,000
$30.0 P/Share
|
|
Jul 05
2022
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+47.43%
|
$75,000
$3.5 P/Share
|
|
Jun 24
2022
|
Gabrielle Sulzberger |
BUY
Exercise of conversion of derivative security
|
Direct |
14,270
+18.26%
|
-
|
|
Apr 13
2022
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
45,000
-95.79%
|
$1,530,000
$34.65 P/Share
|
|
Apr 13
2022
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+48.92%
|
$135,000
$3.5 P/Share
|
|
Mar 31
2022
|
Pf Equity Holdings 1 B.V. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
27,349,211
-100.0%
|
-
|
|
Mar 29
2022
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-83.47%
|
$350,000
$35.0 P/Share
|
|
Mar 29
2022
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+45.5%
|
$30,000
$3.5 P/Share
|
|
Mar 18
2022
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-90.99%
|
$640,000
$32.5 P/Share
|
|
Mar 18
2022
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+47.64%
|
$60,000
$3.5 P/Share
|
|
Mar 16
2022
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-92.66%
|
$750,000
$30.0 P/Share
|
|
Mar 16
2022
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+48.1%
|
$75,000
$3.5 P/Share
|
|
Mar 09
2022
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
30,000
-73.01%
|
$990,000
$33.75 P/Share
|
|
Mar 09
2022
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+48.4%
|
$90,000
$3.5 P/Share
|
|
Mar 02
2022
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-92.66%
|
$750,000
$30.0 P/Share
|
|
Mar 02
2022
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+48.1%
|
$75,000
$3.5 P/Share
|
|
Feb 09
2022
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-92.66%
|
$750,000
$30.0 P/Share
|
|
Feb 09
2022
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+48.1%
|
$75,000
$3.5 P/Share
|
|
Jan 04
2022
|
Norbert G Riedel |
BUY
Exercise of conversion of derivative security
|
Direct |
14,270
+25.0%
|
-
|
|
Dec 27
2021
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,127
-67.58%
|
$144,445
$35.0 P/Share
|
|
Dec 27
2021
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,127
+40.33%
|
$12,381
$3.5 P/Share
|
|
Dec 23
2021
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,873
-74.79%
|
$205,555
$35.0 P/Share
|
|
Dec 23
2021
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,873
+42.79%
|
$17,619
$3.5 P/Share
|
|
Dec 21
2021
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,300
-78.66%
|
$233,600
$32.5 P/Share
|
|
Dec 21
2021
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,300
+44.03%
|
$21,900
$3.5 P/Share
|
|
Dec 17
2021
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,122
-78.25%
|
$227,904
$32.5 P/Share
|
|
Dec 17
2021
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,122
+43.9%
|
$21,366
$3.5 P/Share
|
|
Dec 16
2021
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,578
-73.8%
|
$178,496
$32.5 P/Share
|
|
Dec 16
2021
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,578
+42.46%
|
$16,734
$3.5 P/Share
|
|
Dec 15
2021
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-92.66%
|
$750,000
$30.02 P/Share
|
|
Dec 15
2021
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+48.1%
|
$75,000
$3.5 P/Share
|
|
Nov 10
2021
|
John Renger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
55,000
-57.74%
|
$2,200,000
$40.48 P/Share
|
|
Nov 10
2021
|
John Renger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
55,000
+50.0%
|
$165,000
$3.5 P/Share
|
|
Sep 24
2021
|
Marijn E Dekkers |
BUY
Exercise of conversion of derivative security
|
Direct |
14,270
+25.0%
|
-
|
|
Aug 26
2021
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
68,047
+1.32%
|
$2,041,410
$30.23 P/Share
|
|
Aug 25
2021
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
61,387
+1.21%
|
$1,718,836
$28.57 P/Share
|
|
Aug 24
2021
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
69,761
+1.39%
|
$1,883,547
$27.73 P/Share
|
|
Aug 23
2021
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
44,437
+0.9%
|
$1,110,925
$25.78 P/Share
|
|
Jul 07
2021
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
200,000
+3.97%
|
$5,000,000
$25.0 P/Share
|
|
Jun 24
2021
|
Gabrielle Sulzberger |
BUY
Exercise of conversion of derivative security
|
Direct |
14,270
+22.33%
|
-
|